Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: Efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

Journal of Immunology

Volumn 174, Issue 10, 2005, Pages 6332-6339

  Dietrich, Jes ^a   Aagaard, Claus ^a   Leah, Robert ^a   Olsen, Anja W ^a   Stryhn, Anette ^a   Doherty, T Mark ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; EARLY SECRETORY ANTIGENIC TARGET 6; HYBRID PROTEIN; MYCOBACTERIUM VACCINE; PROTEIN AG85B; PROTEIN SUBUNIT; PROTEIN TB10 4; REAGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFICACY; FEMALE; MOLECULAR RECOGNITION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBERCULOSIS;

EID: 18644373991     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.10.6332     Document Type: Article

References (40)

1. Anonymous. 2002. Global Tuberculosis Control. WHO Report 2002. World Health Organization. Geneva, p. 181.
2. Brewer, T. F. 2000. Preventing tuberculosis with bacillus Catmette-Guérin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 31(Suppl. 3): S64-S67.
3. Fine, P. E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
4. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. J. Am. Med. Assoc. 271: 698-702.
5. Sterne, J. A., L. C. Rodrigues, and I. N. Guedes. 1998. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2: 200-207.
6. Mittal, S. K., V. Aggarwal, A. Rastogi, and N. Saini. 1996. Does B.C.G. vaccination prevent or postpone the occurrence of tuberculosis meningitis? Indian J. Pediatr. 63: 659-664.
7. Brewer, T. F., and G. A. Colditz. 1995. Bacille Calmette-Guerin vaccination for the prevention of tuberculosis in health care workers. Clin. Infect. Dis. 20: 136-142.
8. Colditz, G. A., C. S. Berkey, F. Mosteller, T. F. Brewer, M. E. Wilson, E. Burdick, and H. V. Fineberg. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96: 29.
9. Andersen, P. 1994. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62: 2536.
10. Olsen, A. W., L. A. van Pinxteren, L. M. Okkels, P. B. Rasmussen, and P. Andersen. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect. Immun. 69: 2773.
11. Olsen, A. W., A. Williams, L. M. Okkels, G. Hatch, and P. Andersen. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72: 6148-6150.
12. Horwitz, M. A., B. W. Lee, B. J. Dillon, and G. Harth. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 92: 1530-1534.
13. Huygen, K., J. Content, O. Denis, D. L. Montgomery, A. M. Yawman, R. R. Deck, C. M. DeWitt, I. M. Orme, S. Baldwin, C. D'Souza, et al. 1996. Immunogenecity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2: 893-898.
14. Tascon, R. E., M. J. Colston, S. Ragno, E. Stavropoulos, D. Gregory, and D. B. Lowrie. 1996. Vaccination against tuberculosis by DNA injection. Nat. Med. 2: 888-892.
15. Harboe, M., H. G. Wiker, G. Ulvund, A. S. Malin, H. Dockrell, A. Holm, M. C. Jorgensen, and P. Andersen. 1998. B cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. Infect. Immun. 66: 717-723.
16. Silver, R. F., R. S. Wallis, and J. J. Ellner. 1995. Mapping of T cell epitopes of the 30-kDa α antigen of Mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J. Immunol. 154: 4665-4674.
17. + T-cell lines. Infect. Immun. 68: 3933-3940.
18. Roche, P. W., P. W. Peake, H. Billman-Jacobe, T. Doran, and W. J. Britton. 1994. T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis. Infect. Immun. 62: 5319-5326.
19. Kamath, A. T., C. G. Feng, M. Macdonald, H. Briscoe, and W. J. Britton. 1999. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 67: 1702-1707.
20. Feng, C. G., U. Palendira, C. Demangel, J. M. Spratt, A. S. Malin, and W. J. Britton. 2001. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69: 4174-4176.
21. Lozes, E., K. Huygen, J. Content, O. Denis, D. L. Montgomery, A. M. Yawman, P. Vandenbussche, J. P. Van-Vooren, A. Drowart, J. B. Ulmer, et al. 1997. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 15: 830-833.
22. Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97: 13853-13858.
23. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacteriat immunity in humans. Nat. Med. 10: 1240-1244.
24. Langermans, J. A., T. M. Doherty, R. A. Vervenne, T. Laan, K. Lyashchenko, R. Greenwald, E. M. Agger, C. Aagaard, H. Weiler, D. Soolingen, et al. 2005. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
25. Doherty, T. M., A. W. Olsen, J. Weischenfeldt, K. Huygen, S. D'Souza, T. K. Kondratieva, V. V. Yeremeev, A. S. Apt, B. Raupach, L. Grode, et al. 2004. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J. Infect. Dis. 190: 2146-2153.
26. Brock, I., K. Weldingh, E. M. Leyten, S. M. Arend, P. Ravn, and P. Andersen. 2004. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J. Clin. Microhiol. 42: 2379-2387.
27. Lalvani, A., A. A. Pathan, H. McShane, R. J. Wilkinson, M. Latif, C. P. Conlon, G. Pasvol, and A. V. Hill. 2001. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am. J. Respir. Crit. Care Med. 163: 824-828.
28. Ravn, P., A. Demissie, T. Eguale, H. Wondwosson, D. Lein, H. Amoudy, A. S. Mustafa, A. K. Jensen, A. Holm, I. Rosenkrands, et al. 1999. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179: 637-645.
29. Skjot, R. L., T. Oettinger, I. Rosenkrands, P. Ravn, I. Brock, S. Jacobsen, and P, Andersen. 2000. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. 68: 214-220.
30. Skjot, R. L., I. Brock, S. M. Arend, M. E. Munk, M. Theisen, T. H. Ottenhoff, and P. Andersen. 2002. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect. Immun. 70: 5446-5453.
31. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537.
32. Hall, M. N., J. Gabay, M. Debarbouille, and M. Schwartz. 1982. A role for mRNA secondary structure in the control of translation initiation. Nature 295: 616-618.
33. Brandt, L., M. Elhay, I. Rosenkrands, E. B. Lindblad, and P. Andersen. 2000. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68: 791-795.
34. Brandt, L., T. Oettinger, A. Holm, and P. Andersen. 1996. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol. 157: 3527-3533.
35. Oettinger, T., M. Jorgensen, A. Ladefoged, K. Haslov, and P. Andersen. 1999. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber. Lung Dis. 79: 243-250.
36. Carozzi, S., M. Salit, A. Cantaluppi, M. G. Nasini, S. Barocci, S. Cantarella, and S. Lamperi. 1989. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J. Clin. Microbiol. 27: 1748-1753.
37. Olsen, A. W., P. R. Hansen, A. Holm, and P. Andersen. 2000. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur. J. Immunol. 30: 1724-1732.
38. Vordermeier, H. M., M. A. Chambers, P. J. Cockle, A. O. Whelan, J. Simmons, and R. G. Hewinson. 2002. Correlation of ESAT-6-specific γ interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. 70: 3026-3032.
39. Doherty, T. M., A. Demissie, J. Olobo, D. Wolday, S. Britton, T. Eguale, P. Ravn, and P. Andersen. 2002. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40: 704-706.
40. Lalvani, A., P. Nagvenkar, Z. Udwadia, A. A. Pathan, K. A. Wilkinson, J. S. Shastri, K. Ewer, A. V. Hill, A. Mehta, and C. Rodrigues. 2001. Enumeration of T cells specific for RDI-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J. Infect. Dis. 183: 469-477.